reports
Avinger Reports Third Quarter 2019 Financial Results
Avinger Reports Third Quarter 2019 Financial Results Increased Utilization Drives 33% Growth in Catheter Sales and Gross Margin ExpansionTotal Pantheris Revenue Increases 81% Year-over-Year REDWOOD CITY, Calif., Nov. 05, 2019 (GLOBE NEWSWIRE) -- Avinger, Inc. (Nasdaq: AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of patients with Peripheral Artery Disease (PAD), today reported results for the quarter ended September 30, 2019. Third Quarter Highlights Increased revenue 19% year-...
Avinger Closes $4.5 Million Equity Offering
Avinger Closes $4.5 Million Equity Offering REDWOOD CITY, Calif., Aug. 26, 2019 (GLOBE NEWSWIRE) -- Avinger, Inc. (Nasdaq: AVGR), a leading developer of innovative treatments for Peripheral Artery Disease (PAD) today announced the closing of an underwritten public offering of 3,813,559 shares of its common stock at a price of $1.18 per share, for total gross proceeds of approximately $4.5 million, before deducting underwriting discounts, commissions and other offering expenses payable by the Company. Additionally, the Company has granted the underwriters a 45-day option to purchase up to ...
Avinger Prices $4.5 Million Underwritten Public Offering of Common Sto...
Avinger Prices $4.5 Million Underwritten Public Offering of Common Stock REDWOOD CITY, Calif., Aug. 21, 2019 (GLOBE NEWSWIRE) -- Avinger, Inc. (Nasdaq: AVGR), a leading developer of innovative treatments for Peripheral Artery Disease (PAD), today announced the pricing of an underwritten public offering with gross proceeds to the Company expected to be approximately $4.5 million before deducting underwriting discounts and commissions and other estimated offering expenses. The proposed offering equates to 3,813,559 shares of the Company’s common stock at a price of $1.18 per share. The Comp...
Avinger Announces Proposed Underwritten Public Offering of Common Stoc...
Avinger Announces Proposed Underwritten Public Offering of Common Stock REDWOOD CITY, Calif., Aug. 21, 2019 (GLOBE NEWSWIRE) -- Avinger, Inc. (Nasdaq: AVGR), a leading developer of innovative treatments for Peripheral Artery Disease (PAD), today announced that it intends to offer shares of its common stock for sale in an underwritten public offering. In addition, the Company expects to grant the underwriter a 45-day option to purchase up to an additional 15 percent of the shares of common stock offered in the public offering solely to cover over-allotments, if any. The Company intends to ...
Avinger Reports 26% Sequential Revenue Growth in Second Quarter 2019
Avinger Reports 26% Sequential Revenue Growth in Second Quarter 2019 Revenue Growth Fuels Strong Operating MetricsPantheris SV Limited Launch at Key U.S. Sites in July REDWOOD CITY, Calif., July 31, 2019 (GLOBE NEWSWIRE) -- Avinger, Inc. (Nasdaq: AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of patients with Peripheral Artery Disease (PAD), today reported results for the quarter ended June 30, 2019. Second Quarter and Recent Highlights Increased revenue 26% from the first quart...
Avinger Announces Pantheris SV Limited Launch and Successful Treatment...
Avinger Announces Pantheris SV Limited Launch and Successful Treatment of First Patients in the United States REDWOOD CITY, Calif., July 29, 2019 (GLOBE NEWSWIRE) -- Avinger, Inc. (Nasdaq: AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced that physicians in four U.S. sites have successfully treated several patients with the Pantheris SV (Small Vessel) image-guided atherectomy system. These initial cases are part of a limited launch a...
Avinger to Announce Second Quarter 2019 Financial Results on July 31, ...
Avinger to Announce Second Quarter 2019 Financial Results on July 31, 2019 REDWOOD CITY, Calif., July 26, 2019 (GLOBE NEWSWIRE) -- Avinger, Inc. (Nasdaq: AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of patients with Peripheral Artery Disease (PAD), today announced that it will release its financial results for the second quarter 2019 after the close of trading on Wednesday, July 31, 2019. The Company will host a conference call beginning at 1:30pm PT/4:30pm ET. Individuals inter...
Avinger to Effect One-for-Ten Reverse Stock Split
Avinger to Effect One-for-Ten Reverse Stock Split REDWOOD CITY, Calif., June 21, 2019 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first-ever image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced that the Company will effect a 1-for-10 reverse stock split of the Company's common stock, which will be effective at 5:00 p.m. Eastern time on Friday, June 21, 2019. As of that date, each 10 shares of issued and outstanding common stock and equivalents will be converted into ...
Avinger Provides First Quarter 2019 Shareholder Update
Avinger Provides First Quarter 2019 Shareholder Update Pantheris Revenue Increases 46% over Prior Year REDWOOD CITY, Calif., May 08, 2019 (GLOBE NEWSWIRE) -- Avinger, Inc. (Nasdaq: AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of patients with Peripheral Artery Disease (PAD), today reported results for the first quarter ended March 31, 2019. First Quarter and Recent Highlights Achieved revenue of $1.8 million for the first quarter of 2019, reflecting typical seasonality within...
Avinger Receives FDA Clearance of Pantheris SV Device
Avinger Receives FDA Clearance of Pantheris SV Device Expands Addressable Market by Allowing for Treatment of Small Vessel Disease REDWOOD CITY, Calif., April 10, 2019 (GLOBE NEWSWIRE) -- Avinger, Inc. (Nasdaq: AVGR), a leading developer of image-guided, catheter-based systems for the diagnosis and treatment of patients with Peripheral Artery Disease (PAD), today announced that the Company received 510(k) clearance from the U.S. Food & Drug Administration (FDA) for its Pantheris SV (Small Vessel) image-guided atherectomy system. Pantheris SV, a product line extension of Avinger’s...
Avinger Provides Fourth Quarter and Full Year 2018 Shareholder Update
Avinger Provides Fourth Quarter and Full Year 2018 Shareholder Update Pantheris Fourth Quarter Revenue Increases 18% Over Prior Quarter REDWOOD CITY, Calif., March 06, 2019 (GLOBE NEWSWIRE) -- Avinger, Inc. (Nasdaq: AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of patients with Peripheral Artery Disease (PAD), today reported results for the fourth quarter and full year ended December 31, 2018. Fourth Quarter and Recent Highlights Achieved revenue of $2.0 million for the fourth...
Avinger to Announce Fourth Quarter and Full Year 2018 Financial Result...
Avinger to Announce Fourth Quarter and Full Year 2018 Financial Results on March 6, 2019 REDWOOD CITY, Calif., Feb. 28, 2019 (GLOBE NEWSWIRE) -- Avinger, Inc. (Nasdaq: AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of patients with Peripheral Artery Disease (PAD), today announced that it will release its financial results for the fourth quarter and full year 2018 after the close of trading on Wednesday, March 6, 2019. The Company will host a conference call beginning at 1:30pm PT/4...
Avinger’s Pantheris SV (Small Vessel) Featured in Live Case Transmis...
Avinger’s Pantheris SV (Small Vessel) Featured in Live Case Transmission at Leipzig Interventional Course (LINC) 2019 REDWOOD CITY, Calif., Jan. 28, 2019 (GLOBE NEWSWIRE) -- Avinger, Inc. (Nasdaq: AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced that its Pantheris® SV (Small Vessel) image-guided atherectomy system was featured in a live case transmission at Leipzig Interventional Course (LINC) 2019, a leading global forum for new methods and technology in the field of vascular medicine held annually in Leipzig, Germany. Pantheris SV...
Avinger Announces Preliminary Analysis of Results from SCAN Clinical S...
Avinger Announces Preliminary Analysis of Results from SCAN Clinical Study OCT Imaging with Pantheris Superior or Equivalent to IVUS on all Parameters REDWOOD CITY, Calif., Dec. 19, 2018 (GLOBE NEWSWIRE) -- Avinger, Inc. (Nasdaq: AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced the release of the preliminary analysis of results from its SCAN clinical study, a post-market study comparing optical coherence tomography (OCT) with intravascular ultrasound (IVUS) as a diagnostic imaging tool in the peripheral arteries. Initial analysis of...
Avinger Announces Successful Treatment of 500th Patient with Next-Gen...
Avinger Announces Successful Treatment of 500th Patient with Next-Generation Pantheris Device 38% Year-over-Year Pantheris Revenue Growth in First Full Quarter of Launch REDWOOD CITY, Calif., Dec. 13, 2018 (GLOBE NEWSWIRE) -- Avinger, Inc. (Nasdaq: AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced that physicians in 59 sites globally have successfully treated more than 500 patients with the next-generation Pantheris image-guided atherectomy system for the treatment of peripheral artery disease (PAD). The next-generation Pantheris w...
Avinger Announces Commercial Launch in Australia
Avinger Announces Commercial Launch in Australia Pantheris Receives Regulatory Clearance and First Patients Treated Successfully with Pantheris in Australia REDWOOD CITY, Calif., Dec. 06, 2018 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company that designs and develops the first-ever image-guided, catheter-based system that diagnoses and treats patients with peripheral artery disease (PAD), today announced the commercial launch of its Pantheris image-guided atherectomy system in Australia. Avinger recently completed an exclusive distribution agree...
Avinger Receives New Patent Covering Pantheris Image-Guided Atherectom...
Avinger Receives New Patent Covering Pantheris Image-Guided Atherectomy System Extensive Intellectual Property Portfolio Now Includes 131 Patents and Applications REDWOOD CITY, Calif., Aug. 29, 2018 (GLOBE NEWSWIRE) -- Avinger, Inc. (Nasdaq: AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced the issuance of an important new patent covering the Company’s Pantheris image-guided atherectomy system. The U.S. Patent and Trademark Office (USPTO) issued U.S. Patent No. 10,052,125, titled “Atherectomy Catheter With Laterally-Displaceable Ti...
Avinger Completes Enrollment in SCAN Clinical Study
Avinger Completes Enrollment in SCAN Clinical Study Post-Market Study Compares Pantheris OCT Imaging with IVUS for Diagnostic Imaging in Peripheral Arteries REDWOOD CITY, Calif., Aug. 23, 2018 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ: AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced that it has completed enrollment in the SCAN clinical study, a post-market study comparing optical coherence tomography (OCT) with intravascular ultrasound (IVUS) as a diagnostic imaging tool in the peripheral arteries. Avinger’s proprietary Lumivascu...
Avinger Announces Second Quarter 2018 Financial Results
Avinger Announces Second Quarter 2018 Financial Results REDWOOD CITY, Calif., Aug. 13, 2018 (GLOBE NEWSWIRE) -- Avinger, Inc. (Nasdaq: AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today reported results for the second quarter ended June 30, 2018. Second Quarter and Recent Highlights Revenue of $2.1 million for the second quarter of 2018, an increase of 14% from $1.8 million in the prior quarterReceived FDA clearance of next generation Pantheris image-guided atherectomy device and announced successful treatment of patients in several centers th...
Avinger to Report Second Quarter 2018 Results on Monday, August 13, 20...
Avinger to Report Second Quarter 2018 Results on Monday, August 13, 2018 REDWOOD CITY, Calif., Aug. 06, 2018 (GLOBE NEWSWIRE) -- Avinger, Inc. (Nasdaq: AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), will announce its second quarter 2018 results for the period ended June 30, 2018 on Monday, August 13, 2018 after market close. A conference call discussing the results will begin at 5:00 PM ET. Conference Call Information Individuals interested in listening to the conference call may do so by dialing (877) 407-8293 for domestic callers or (201) 689...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.